Infian competitors

Chris has been with CPSI since 2000 and transitioned to his current CPSI role in 2015. He also serves as President at TruBridge, a role he has held since 2013. Chris previously served as Vice President of Business Services from 2008-2013. Other previously-held positions include Assistant Director and Director in the Business Management Services division. Chris graduated from Auburn University with a Bachelor of Science in Marketing.

Dr. Ellison has served as our President and Chief Executive Officer since April 2020 and as a Director on our Board since January 2020. Dr. Ellison’s broad experience and leadership positions include Chief Executive Officer of the privately held biotechnology company, Promedior, Inc. (acquired by Roche); President and Chief Executive Officer of Bond Biosciences, Inc., a biotech start-up developing a drug addressing the toxic impact of iron overload in the body; Executive Director of Torreya Advisors, LLC, a life sciences investment banking firm; Chairman and Chief Executive Officer of Assembly Biosciences, Inc. (formerly Ventrus Biosciences, Inc.); Executive Vice President of Paramount Biosciences LLC, a global drug development and healthcare investment firm; Vice President of Clinical Development of FibroGen, Inc., where he played a key role in the early phase development of roxadustat in anemia for chronic kidney disease (CKD) patients; Vice President of Medical Affairs and Chief Medical Officer of Sanofi-Synthelabo US, Inc.; and Vice President, Medical Affairs and Chief Medical Officer of Hoffman La Roche, Inc. in the United States. Dr. Ellison previously served as an Independent Board Director for several private and public companies, including Cougar Biotechnology Inc.; ProSanos Corporation; Cormedix Inc., a cardio-renal clinical stage company; and Mt. Cook, a urology-focused company. Dr. Ellison received a Master of Science degree from the London School of Tropical Medicine and Hygiene, and an M.D. from the University of British Columbia.

Having extensive experience in all facets of AHS’ business and in delivering services that meet the ever-changing needs of today’s healthcare community, David is responsible for AHS’ growth, performance, and strategic direction. Prior to joining AHS, David served as President and/or CEO of several leading, nationally-recognized, healthcare services companies, including AHC, Inc. and Argent Healthcare. Earlier in his career, David held various management positions with Medaphis Physician Services Corp. (now PerSé Technologies) and several other healthcare organizations.

Dr. John H. Hartman MD is a Chief Executive Officer at Visonex and is based in United States.

Joseph Davi H. is a President and Chief Executive Officer at Med Metrix and is based in United States.